AGARWALEYEDr. Agarwal's Health Care Limited
Healthcare · Medical Instruments & Supplies · NSE · as of 2026-09-11 (delayed ~30 min in market hours)
Dr. Agarwal's Health Care Limited operates eye hospitals in India and internationally. It offers cataract surgeries, such as small incision cataract surgery, phacoemulsification, robotic cataract surgery, and glued intraocular lens treatments; and refractive surgeries, including surgical procedures to correct the refractive error of the eye to get rid of or reduce dependence on glasses and contact lens. The company also provides surgical retinal treatments, corneal transplantation and pinhole pupilloplasty, oculoplasty, and surgeries for the treatment of glaucoma and pterygium; doctor consultation services; and diagnostic services for eye disorders along with non-surgical treatments, including retinal laser therapy and dry eye treatment services. It also sells glasses, lenses, contact lenses, and frames; and eye care-related pharmaceutical products. The company was incorporated in 2010 and is based in Chennai, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on AGARWALEYE — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
The picture
- • Revenue growth: 22.6% YoY
- • Profit growth: 20.8% YoY
- • Debt/Equity: 0.50
- • Price vs SMA50: above
- • Price vs SMA200: above
- • Golden cross setup: SMA50 above SMA200
Bull case
- • Revenue growth: 22.6% YoY
- • Profit growth: 20.8% YoY
- • Debt/Equity: 0.50
- • Price vs SMA50: above
Bear case
- • ROE: 8.3%
- • ROCE: 9.5%
- • MACD: bearish
- • Price vs EMA21: below
Key risks
- • ROE: 8.3%
- • ROCE: 9.5%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹15.17). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.